Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CHKA | P35790 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192586 | 0.88 | HDAC4 (0.56) | NAMPTHDAC4MEN1KMT2AALDH1A1 | |
| SCHEMBL2396123 | 0.86 | HDAC4 (0.58) | NAMPTHDAC4MEN1KMT2AALDH1A1 | |
| SCHEMBL4030523 | 0.86 | HDAC4 (0.61) | NAMPTHDAC4MEN1KMT2AMAPT | |
| SCHEMBL28044690 | 0.81 | SIGMAR1 (0.47) | MEN1KMT2AMAPTSIGMAR1KDM4E | |
| SCHEMBL238334 | 0.81 | MEN1 (0.66) | NAMPTHDAC4MEN1KMT2AALDH1A1 | |
| SCHEMBL3079800 | 0.81 | MEN1 (0.48) | NAMPTCHRM4MEN1KMT2AALDH1A1 | |
| SCHEMBL6747177 | 0.81 | NAMPT (0.53) | NAMPTHDAC4MEN1KMT2AMAPT | |
| SCHEMBL2395803 | 0.80 | LMNA (0.60) | NAMPTHDAC4MEN1KMT2ASIGMAR1 | |
| SCHEMBL6585625 | 0.80 | DRD4 (0.63) | NAMPTHDAC4MEN1KMT2ASIGMAR1 | |
| SCHEMBL15783743 | 0.80 | HDAC4 (0.63) | NAMPTHDAC4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013157-B2 | Synthesis of unsaturated piperidines from piperidones with a silyl reagent | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8013157-B2 | Synthesis of unsaturated piperidines from piperidones with a silyl reagent | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8013157-B2 | Synthesis of unsaturated piperidines from piperidones with a silyl reagent | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | NEELAKANDHA MANI S | 2010-12-23 | — | — | US | disclosed |
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | NEELAKANDHA MANI S | 2010-12-23 | — | — | US | disclosed |
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | NEELAKANDHA MANI S | 2010-12-23 | — | — | US | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| EP-2120572-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | Janssen Pharmaceutica, N.V. (BE) | 2009-11-25 | — | — | EP | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2008079255-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079255-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | NAMPT 1794/4885HDAC4 297/4885CHRM4 4849/4885 |
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | THPO, DHPS, PIR | NAMPT 1792/4885HDAC4 205/4885CHRM4 4454/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | NAMPT 1915/4885HDAC4 262/4885CHRM4 4878/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | NAMPT 1794/4885HDAC4 297/4885CHRM4 4849/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | NAMPT 1373/4885HDAC4 177/4885CHRM4 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.